Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017:2017:9876819.
doi: 10.1155/2017/9876819. Epub 2017 Jun 18.

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera

Affiliations
Clinical Trial

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera

Sara C Meyer et al. Biomed Res Int. 2017.

Abstract

Background: Myeloproliferative neoplasms (MPN) encounter thromboses due to multiple known risk factors. Heparin-induced thrombocytopenia (HIT) is a thrombotic syndrome mediated by anti-platelet factor 4 (PF4)/heparin antibodies with undetermined significance for thrombosis in MPN. We hypothesized that anti-PF4/heparin Ab might occur in MPN and promote thrombosis.

Methods: Anti-PF4/heparin antibodies were analyzed in 127 MPN patients including 76 PV and 51 ET. Screening, validation testing, and isotype testing of anti-PF4/heparin Ab were correlated with disease characteristics.

Results: Anti-PF4/heparin antibodies were detected in 21% of PV and 12% of ET versus 0.3-3% in heparin-exposed patients. Validation testing confirmed anti-PF4/heparin immunoglobulins in 15% of PV and 10% of ET. Isotype testing detected 9.2% IgG and 5.3% IgM in PV and exclusively IgM in ET. IgG-positive PV patients encountered thromboses in 57.1% suggesting anti-PF4/heparin IgG may contribute to higher risk for thrombosis in MPN. Overall, 45% of PV patients experienced thromboses with 11.8% positive for anti-PF4/heparin IgG versus 7.1% in PV without thrombosis.

Conclusion: Anti-PF4/heparin antibodies occur endogenously and more frequently in MPN than upon heparin exposure. Thrombotic risk increases in anti-PF4/heparin IgG-positive PV reflecting potential implications and calling for larger, confirmatory cohorts. Anti-PF4/heparin IgG should be assessed upon thrombosis in PV to facilitate avoidance of heparin in anti-PF4/heparin IgG-positive PV.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Endogenous anti-PF4/heparin IgG and IgM antibodies occur in polycythemia vera and essential thrombocythemia. (a) Anti-PF4/heparin antibodies of IgG isotype are detected at considerable frequency in polycythemia vera (PV), while IgM isotype antibodies are also found. (b) Anti-PF4/heparin antibodies in essential thrombocythemia are of IgM isotype in our cohort. No IgA isotypes were detected. PF4: platelet factor 4; Ig: immunoglobulin.

Similar articles

Cited by

References

    1. Arber D. A., Orazi A., Hasserjian R., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544. - DOI - PubMed
    1. Tefferi A., Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncology. 2015;1(1):97–105. doi: 10.1001/jamaoncol.2015.89. - DOI - PubMed
    1. Rampal R., Al-Shahrour F., Abdel-Wahab O., et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123–e133. doi: 10.1182/blood-2014-02-554634. - DOI - PMC - PubMed
    1. Meyer S. C., Levine R. L. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clinical Cancer Research. 2014;20(8):2051–2059. doi: 10.1158/1078-0432.CCR-13-0279. - DOI - PMC - PubMed
    1. Parganas E., Wang D., Stravopodis D., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385–395. doi: 10.1016/S0092-8674(00)81167-8. - DOI - PubMed

Publication types